Skip to main content
OpenTrials
Completed

NCT Number: NCT04690920

Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Corona Virus Disease 2019 (COVID-19) COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The University of Lahore

Lahore, Punjab Province, 54000, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy

Exclusion criteria

Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent

Treatment and study plan

Tocilizumab

Drug

Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Other names: Remdesivir, Standard treatment with Antibiotic, oxygen, Vitamin C, Statins, No treatment is given to control group

Primary outcomes

  1. Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen

    Time frame: 7 days

Secondary outcomes

  1. Hospital stay

    Time frame: 15 days

  2. Oxygen demand

    Time frame: 7-15 days

  3. Viral load

    Time frame: 7-15 days

    by RT-PCR

Sponsors and collaborators

Lead sponsor

University of Lahore

Other

Registry information

Official study title

Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Dec 31, 2020
Registry last updated
Dec 31, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.